Martin D. Madaus was named President and Chief Executive Officer of Azenta, Inc., succeeding John P. Marotta. As of November 6, 2026, Azenta, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 7, 2026 to September 17, 2026, naming 3 appointments and 3 departures (Form 8-K, August 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Azenta, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Martin D. Madaus · 8-K, 2026-09-17
- · In / out: Out · Person: John P. Marotta · Role: President and Chief Executive Officer · Effective: 2026-08-22 · 8-K, 2026-08-24
- · In / out: In · Person: Erik J. Bello · Role: Chief Accounting Officer · 8-K, 2026-08-11
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-07
Azenta, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-07 to 2026-09-17. They name 3 people, with 3 appointments and 3 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Azenta, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-10-07 (layoff filings and notices).
Also on the record for Azenta, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.35% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 4.6% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Azenta, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Azenta, Inc. and the records around it.
Azenta, Inc. elsewhere on the record
Companies that share a holder
- Dimensional Fund Advisors LP also filed stake reports on 366 other companies: Acadia Healthcare Co Inc (Oct 2026), ADT Inc (Oct 2026), AGCO Corp (Oct 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Azenta, Inc.
Get an email when Azenta, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Azenta, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Azenta, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Azenta, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-17 | Out | 8-K, 2026-09-17 | |||
| 2026-08-24 | Out | President and Chief Executive Officer | 2026-08-22 | 8-K, 2026-08-24 | |
| 2026-08-24 | In | President and Chief Executive Officer | 8-K, 2026-08-24 | ||
| 2026-08-24 | Out | 8-K, 2026-08-24 | |||
| 2026-08-11 | In | Chief Accounting Officer | 8-K, 2026-08-11 | ||
| 2026-08-11 | In | 8-K, 2026-08-11 | |||
| 2026-04-07 | Reported | not named in the filing | 8-K, 2026-04-07 |
Who leads Azenta, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Martin D. Madaus, appointed (filed 2026-08-24).
- Chief Accounting Officer: Erik J. Bello, appointed (filed 2026-08-11).
New leaders reset buying decisions — get the Full Report on Azenta, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at Azenta, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Azenta, Inc.Every change, in the filing's words
Departing: Martin D. Madaus
Also on September 14, 2026, the Board reconstituted the Nominating and Governance Committee to consist of William L. Cornog, as Chair, Frank E. Casal, and Robyn C. Davis, and Dr. Madaus ceased serving as a member of that committee.
- On September 14, 2026, upon the recommendation of the Human Resources and Compensation Committee (the "Committee") of the Board, the Board approved, and the Company entered into, a letter agreement with Dr. Madaus (the "Letter Agreement") setting forth the terms of his employment as Interim President and Chief Executive Officer.
- The Letter Agreement provides for an annual base salary of $600,000, effective as of the Start Date, and a cash performance recognition bonus equal to 100% of his annual base salary in lieu of participation in the Company's annual incentive compensation plan.
- Any earned and vested performance recognition bonus will be paid in a lump sum on January 1, 2028, subject to Dr. Madaus's execution and non-revocation of a general release of claims.
- The Letter Agreement also provides for the grant to Dr. Madaus, as of September 14, 2026 (the "CEO Grant Date"), of restricted stock units under the Plan having an award value of $1,200,000.
- The number of restricted stock units subject to the award is determined by dividing $1,200,000 by the average closing price of the Company's common stock over the 20 trading days ending on and including the CEO Grant Date.
Departing: John P. Marotta, President and Chief Executive Officer, effective 2026-08-22
On August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the "Company") and as a member of the Company's Board of Directors (the "Board"), effective as of August 22, 2026 (the "Effective Date").
Appointed: Martin D. Madaus, President and Chief Executive Officer
On August 22, 2026, the Board elected Dr. Martin D. Madaus as the Company's Interim President and Chief Executive Officer, effective as of the Effective Date.
Departing: Martin D. Madaus
During his interim service as an executive officer of the Company, Dr. Madaus will step down as Chair and a member of the Nominating and Governance Committee of the Board.
- Mr. Marotta's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In connection with Mr. Marotta's resignation, the Board reduced the size of the Board from nine to eight members.
- Dr. Madaus has served as a member of the Board since January 2024 and is the Chair of the Nominating and Governance Committee of the Board.
- Dr. Madaus also assumed the duties of the Company's principal executive officer for Securities and Exchange Commission reporting purposes as of the Effective Date.
- Dr. Madaus will continue to serve as a member of the Board.
- Dr. Madaus, age 66, currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $485 billion in assets under management.
- Dr. Madaus has notable experience in strategy, mergers and acquisitions, and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led its sale to Merck KGaA (FWB: MRK) for $7.2 billion, and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics.
- Dr. Madaus previously served as Chairman and CEO of Ortho Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp., a subsidiary of Roche Holdings AG (SWX: ROG).
Appointed: Erik J. Bello, Chief Accounting Officer
(c) On August 6, 2026, the Board of Directors (the "Board") of Azenta, Inc. (the "Company") appointed Erik J. Bello, age 51, as the Company's Vice President, Chief Accounting Officer, effective upon the commencement of his employment with the Company, which is expected to occur on August 31, 2026 (the "Effective Date").
Appointed: Erik J. Bello
Mr. Bello will serve as the Company's principal accounting officer as of the Effective Date.
- Lawrence Lin, the Company's Executive Vice President and Chief Financial Officer, who has also served as the Company's principal accounting officer, will cease to serve as principal accounting officer as of the Effective Date and will continue to serve as Executive Vice President and Chief Financial Officer and as the Company's principal financial officer.
- Mr. Bello served as Vice President and Corporate Controller of Onto Innovation Inc., a publicly traded semiconductor company, from February 2025 until joining the Company, and as Vice President and Corporate Controller of UniFirst Corporation, a publicly traded provider of workplace uniforms and protective workwear, from October 2020 to February 2025.
- He previously held senior accounting and financial reporting positions at PAREXEL International Corporation, Mevion Medical Systems, Inc. and Analogic Corporation, and began his career at KPMG LLP.
- Mr. Bello holds a B.S. in Accounting from the University of Maryland and is a certified public accountant.
Reported
On April 6, 2026, Ginger Zhou stepped down from her role as President of the Multiomics business of Azenta, Inc. (the "Company").
- Dr. Zhou's decision to step down was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Dr. Zhou will continue to support the Company in an advisory capacity through November 2026 pursuant to a consulting services agreement dated April 7, 2026 providing for an initial consulting fee of $103,500, payable in seven equal monthly installments through the term and subject to proration for a term of less than seven months.
- On April 6, 2026, Dr. Zhou entered into a separation agreement to memorialize the termination of her employment and provide a general release of claims against the Company.
- In this role, Mr. Martin reports to John Marotta, the Company's President and Chief Executive Officer.
- Mr. Martin most recently served as Chief Executive Officer of Maravai LifeSciences Holdings, Inc. (Nasdaq: MRVI), a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease.
- He served as Maravai's Chief Executive Officer from July 2023 to June 2025 and from September to October 2022, as well as President of Maravai's Biologics Safety Testing operating division from December 2022 to July 2023.
- Mr. Martin also was a member of the board of directors of Maravai from July 2024 to June 2025.
Tools for this story
Each opens in a new tab, filled in for Azenta, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.